Informations générales (source: ClinicalTrials.gov)
Jejunal Luminal and Colonic Mucosa-Associated Microbiota in Metabolic Diseases: Methods, Identification and Causalities (JE/COL-MIME)
Observational [Patient Registry]
Institut National de la Santé Et de la Recherche Médicale, France (Voir sur ClinicalTrials)
janvier 2022
juin 2025
05 avril 2025
This clinical study will investigate Jejunal Microbiota in Metabolic Diseases (Je-MiMe,
n=45) and Colonic mucosa-associated Microbiota in Metabolic Diseases (Col-MiMe, n=45).
Each cohort (Je and Col -MiMe) is composed of three groups: participants with obesity
(n=15) with obesity and with type II diabetes (n=15).
This research protocol is organized in two parts. Each part of this study will recruit 45
participants that are only recruited in one of the parts of the protocol (JE-MIME or
COL-MIME). Thus, in total, the study will include 90 patients. Each part of this study is
composed of 3 groups: 1) "Control Group ", 2) Obese group (Ob), 3) Obese and Type 2
Diabetes group (ObD). Control groups for part I (JE-MIME) and part 2 (COL-MIME) are
composed of different participants. Each group is composed of 15 human adult volunteers
for the JE-MIME study (part 1) and 15 participants for the COL-MIME study (part 2). Total
number of participants is 45 for part 1, and 45 for part 2. Total number for this project
is 90.
Microbiota wil be collected during an endoscopy or coloscopy which is planned as routine
care for the patients.
Primary objectives are to characterize jejunal (JE-MIME, Part I of the study) and colonic
mucosa-associated microbiota (COLMIME, Part II of the study) and compare both microbiota
to faecal microbiota (evaluate differences and similarities between jejunal microbiota or
mucus-associated microbiota and faecal microbiota).
Secondary objectives are to 1) Correlate microbiota with metabolic health and
inflammatory markers; 2) Correlate microbiota with lifestyle and neuropsychological
health.
Both the jejunal microbiota and mucus-associated microbiota are strong integrators of
nutritional environment and intestinal health status, respectively, compared to the fecal
microbiota. This study will help to better understand the physiopathology of metabolic
diseases. This research could lead to finding specific microbiota members, either from
the jejunal compartment or from the inner mucus layer, crucial for the promotion /
protection of chronic intestinal inflammation and associated metabolic health.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL PRIVE DES PEUPLIERS | Gianfranco DONATELLI, Dr | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- General Inclusion Criteria:
- Aged between 18 and 60 years;
- Ability to understand and provide informed consent (in French);
- Ability and willingness to meet the required schedule and study procedures;
- Group-Specific Inclusion Criteria:
- Control Group
Inclusion criteria for the participants from the Control group are:
- Presence of Gastroesophageal Reflux Disease symptoms or gastric discomfort.
- BMI [19kg/m² < BMI <25 kg/m²]
- Match age and sex to the patients from the Ob and ObD groups.
- Only patients with normal glucose tolerance (NGT), glucose tolerance (IGT) and/or
fasting glucose (IFG) and an HbA1c < 6.5 % will be included in this group.
- Ob Group
Inclusion criteria for the participants from Ob and ObD groups are:
● Candidate for bariatric surgery and meet the HAS criteria (Haute Autorité de Santé,
2009) :
- IMC ≥ 40 kg/m² without comorbidities Or IMC≥ 35 kg/m² with at least one
obesity-related comorbidity (i.e.: Hypertension, Dyslipidemia, Obstructive Sleep
Apnea, Joints Disease, non-alcoholic steatohepatitis, excluding T2D)
- Weight stable for at least 2 months
- No treatment for metabolic health complications, no previous obesity surgery, no
obesity treatment drug.
- No monogenic form of obesity (Hebebrand et al., 2017)
- ObD Group
Inclusion criteria for the participants from ObD groups are:
- Candidate for bariatric surgery with T2D
- At least one obesity-related comorbidity including T2D
- Fasting plasma glucose (FPG) ≥7 mM (=1.26g/l) or
- Participants with HbA1c ≥ 6.5% (48 mmol/mol)
- All stages of albuminuria
- General Inclusion Criteria:
- Aged between 18 and 60 years;
- Ability to understand and provide informed consent (in French);
- Ability and willingness to meet the required schedule and study procedures;
- Group-Specific Inclusion Criteria:
- Control Group
Inclusion criteria for the participants from the Control group are:
- Presence of Gastroesophageal Reflux Disease symptoms or gastric discomfort.
- BMI [19kg/m² < BMI <25 kg/m²]
- Match age and sex to the patients from the Ob and ObD groups.
- Only patients with normal glucose tolerance (NGT), glucose tolerance (IGT) and/or
fasting glucose (IFG) and an HbA1c < 6.5 % will be included in this group.
- Ob Group
Inclusion criteria for the participants from Ob and ObD groups are:
● Candidate for bariatric surgery and meet the HAS criteria (Haute Autorité de Santé,
2009) :
- IMC ≥ 40 kg/m² without comorbidities Or IMC≥ 35 kg/m² with at least one
obesity-related comorbidity (i.e.: Hypertension, Dyslipidemia, Obstructive Sleep
Apnea, Joints Disease, non-alcoholic steatohepatitis, excluding T2D)
- Weight stable for at least 2 months
- No treatment for metabolic health complications, no previous obesity surgery, no
obesity treatment drug.
- No monogenic form of obesity (Hebebrand et al., 2017)
- ObD Group
Inclusion criteria for the participants from ObD groups are:
- Candidate for bariatric surgery with T2D
- At least one obesity-related comorbidity including T2D
- Fasting plasma glucose (FPG) ≥7 mM (=1.26g/l) or
- Participants with HbA1c ≥ 6.5% (48 mmol/mol)
- All stages of albuminuria
- General Non-inclusion Criteria:
- Treatment for the previous 12 week that could
- alter gastrointestinal motor function (e.g. opioids, prokinetics,
anticholinergics, laxatives),
- acidity (PPI, H2RA)
- microbial population (e.g.: antibiotics, probiotics)
- immunosuppressants (eg: calcineurin inhibitors, corticosteroids,
biological agents, etc.).
- use of weight-loss drug or dietary intervention aiming to lose weight;
- Altered anatomy of the esophagus, stomach, small or large intestine due to
prior gastrointestinal surgery (exceptions include appendectomy or
cholecystectomy more than 3 months prior to enrollment) or other reasons;
- Any abdominal or pelvic surgery within the past 3 months;
- Diverticulitis, diverticular stricture, or other intestinal strictures.
- Intestinal resection of the gastrointestinal tract
- Previous history of gastric bezoar or gastroparesis
- Acute or chronic inflammatory bowel disease or infections diseases (i.e.: VHC,
VHB, VIH, etc.)
- Abdominal or pelvic radiotherapy or abdominal cancer
- Colorectal cancer, either known or not
- Dysphagia, eosinophilic esophagitis, esophageal stricture, or other swallowing
disorder
- Organ Transplantation and patients on Immunosuppressive Therapy
- Severe kidney failure and/or patients on dialysis therapy (serum creatinine >
150 μmol/l or eGFR < 60 ml/min per 1.73 m2 body surface area)
- CVD, endocrine, renal or other chronic disease likely to affect motility.
- Colon cleansing preparation during the last 1 month
- No < 3 bowel movements per week
- Females of childbearing age who do not practice birth control and/or are
pregnant or lactating
- Participants non-affiliated to the French national health scheme
- Participants who are already included in a clinical study which implies testing
any pharmaceutical drug.
- Participants who do not understand the research procedures those who are
institutionalized, or who unable to give informed consent
- Participants placed under legal protection
- Patients with drug addiction
- Antibiotherapy 3 months preceding the endoscopy
- Weight variation (diminution or increase) > 5kg in the last 3 months
- Specific non-inclusion Criteria
- Ob and ObT2D Group
- Usual contraindication for bariatric surgery;